Dr. Andrea Apolo

And they also have a monotherapy PEMBRO arm. And then they have a no therapy arm where they get no therapy in the neoadjuvant and no therapy in the adjuvant setting. So I'm excited about these trials.

And they also have a monotherapy PEMBRO arm. And then they have a no therapy arm where they get no therapy in the neoadjuvant and no therapy in the adjuvant setting. So I'm excited about these trials.

I think that, you know, if we see this fantastic activity that we saw in the metastatic setting, now in the perioperative setting with no concerns about surgical outcomes, then I think this will be the new standard of care. So those are the trials that I am really waiting to hear about. the results of over the next few years.

I think that, you know, if we see this fantastic activity that we saw in the metastatic setting, now in the perioperative setting with no concerns about surgical outcomes, then I think this will be the new standard of care. So those are the trials that I am really waiting to hear about. the results of over the next few years.

I think that, you know, if we see this fantastic activity that we saw in the metastatic setting, now in the perioperative setting with no concerns about surgical outcomes, then I think this will be the new standard of care. So those are the trials that I am really waiting to hear about. the results of over the next few years.

This was great. You asked such great questions that are really important and that we're dealing with on a daily basis. And how do we now take this data that we just saw at ESMO and apply it to our clinic? And I think we're still figuring that out. So it's fun to have these conversations. And I think the conversations will be evolving. So more to come.

This was great. You asked such great questions that are really important and that we're dealing with on a daily basis. And how do we now take this data that we just saw at ESMO and apply it to our clinic? And I think we're still figuring that out. So it's fun to have these conversations. And I think the conversations will be evolving. So more to come.

This was great. You asked such great questions that are really important and that we're dealing with on a daily basis. And how do we now take this data that we just saw at ESMO and apply it to our clinic? And I think we're still figuring that out. So it's fun to have these conversations. And I think the conversations will be evolving. So more to come.

Social media and PR by Chi Ding. Administrative support provided by Jamila Kinabru.

Social media and PR by Chi Ding. Administrative support provided by Jamila Kinabru.

Social media and PR by Chi Ding. Administrative support provided by Jamila Kinabru.